Tango Therapeutics prices $600M upsized offering at $30, signaling significant dilution
TNGX has more than doubled off its 52-week low of $3.77 on elevated volume (2.1× avg).
Summary
Tango Therapeutics has priced an upsized public offering of $600 million in common stock at $30.00 per share. This follows the proposed $500 million offering announced yesterday, indicating increased capital needs or strong demand. The $600 million raise is highly dilutive, representing over 13% of the company's current market capitalization. While it significantly bolsters the company's cash reserves, the pricing below the current market price of $31.74 is likely to exert downward pressure on the stock.
At the time of this announcement, TNGX was trading at $31.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.6B. The 52-week trading range was $3.77 to $32.79. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Reuters.